RecruitingNot ApplicableNCT07355023

AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study

Sponsor

Tri-Service General Hospital

Enrollment

5,000 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Left Ventricular (LV) Systolic Dysfunction

Summary

This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

With an ECG followed by an echocardiogram within a 90-day interval
With preserved left ventricular ejection fraction (LVEF ≥ 50%)

Exclusion Criteria3

missing essential variables or ECG lead data
any prior LVEF < 50%
loss to follow-up or death during the 90-day assessment window

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALGuideline-directed medical therapies

Guideline-directed medical therapies for patients at risk of heart failure, including angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) , beta-blockers and sodium-glucose cotransporter 2 (SGLT2) inhibitors.